LVTS - Laboratory for Vascular Translational Science

What LVTS - Laboratory for Vascular Translational Science does

LVTS (Laboratory for Vascular Translational Science, INSERM U1148) is a French public research laboratory founded circa 2007 and operating across three sites in the Paris region (Paris-Xavier Bichat Hospital, Bobigny, and Villetaneuse), with more than 240 collaborators including 110 permanent positions. Affiliated with INSERM, Université Paris Cité, and Université Sorbonne Paris Nord, the lab is organized into six collaborative research teams covering cardiovascular immunobiology, integrative biology of arterial diseases and genetic risk factors, biomedical engineering with tissue engineering and immersive technologies, nanotechnologies for vascular medicine and imaging, atherothrombotic disease in heart and brain, and serpins and hemostasis.

Core technology comprises a translational pipeline spanning molecular-to-tissue investigation of the heart, valves, macro- and micro-circulation and their interactions with immune, coagulation, and thrombotic systems. The lab operates shared platforms including an Experimental Platform and access to preclinical imaging, and holds granted patents on hybrid polysaccharide/magnetite microgels for photothermal thrombolysis and CD31-mimetic coatings for coronary and flow-diverting stents, with pending applications covering clot-adhesive thrombectomy coatings and microemulsion-inspired polysaccharide nanoparticles (fucoidan-decorated for P-selectin targeting and capable of loading rtPA or DNase I). IP is extended through biotech spin-offs such as PF Guard.

The business model is non-commercial public research. Operating revenue is generated through three streams: public research funding from French national agencies (ANR) and European programs (Horizon Europe, EIT Health) plus institutional support from INSERM and Paris Cité University; industry partnerships and licensing agreements with pharmaceutical and medical device companies; and equity/licensing returns from biotech startups spun out of the lab's research programs. Pricing is not applicable because the lab does not sell commercial products directly; collaboration terms are negotiated individually. Go-to-market is community-led, executed through academic publishing, conference presentations, industry collaborations, and an Innovation & Industrial Partnerships Hub.

Name

LVTS - Laboratory for Vascular Translational Science

Legal name

INSERM U1148 - Laboratory for Vascular Translational Science (LVTS)

Website

https://lvts.fr

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

LVTS (INSERM U1148) is a French public vascular translational science laboratory operating across six specialized research teams in Paris, serving academic, clinical, and industry partners via research programs, technology licensing, and biotech spin-offs.

Ownership category

akta.pro rank

Product category

Vascular Translational Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Vascular translational science
• Cardiovascular research
• Biomedical engineering
• Nanomedicine research
• Clinical research

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Public Research Funding: The laboratory operates primarily through public research funding from French national research agencies (ANR), European Union research programs (EIT Health, Horizon Europe), and institutional support from INSERM and Paris Cité University.
2. Industry Partnerships and Licensing: Revenue generated through collaborative research agreements with pharmaceutical companies, medical device manufacturers, and biotech companies. Technology transfer and licensing of developed intellectual property.
3. Startup Spin-offs: The lab has created startups from its research programs (LVTS's Biotechs), generating potential equity returns and licensing revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

LVTS is a translational research laboratory that conducts basic science research, large clinical trials, and develops new diagnostic markers, imaging technologies, and therapeutic/biomaterial strategies for vascular medicine. It is organized into six collaborative research teams covering cardiovascular immunobiology, arterial diseases and genetic risk, biomedical engineering and tissue engineering, nanotechnologies for vascular medicine, atherothrombotic disease in heart and brain, and serpins and hemostasis. The lab also operates shared technological platforms, including an Experimental Platform and preclinical imaging facilities, and transfers its IP to industry through licensing and biotech spin-offs.

Product overview

LVTS (Laboratory for Vascular Translational Science) is a research institution organized into six collaborative teams affiliated with INSERM and Paris 13 University. The laboratory conducts translational research on vascular pathophysiology, offering no commercial products but rather research programs, technological platforms, and expertise in areas including cardiovascular immunobiology, tissue engineering, nanomedicine, and vascular imaging. The unit operates shared facilities and platforms supporting both basic science approaches and clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• LVTS Collaborative Vascular Research Programs Translational research services organized into six specialized teams covering cardiovascular immunobiology, arterial disease genetics, biomedical engineering and tissue engineering, nanotechnologies for vascular medicine and imaging, atherothrombotic disease, and hemostasis. Delivered to academic, clinical, and industry partners through collaborative research agreements and joint programs.
• Experimental Platform and Preclinical Imaging Platform Shared technological platforms and facilities supporting basic and translational vascular research, including an Experimental Platform and preclinical imaging capabilities, accessed by research collaborators and partners for validation studies.
• LVTS Technology Licensing and Industry Partnerships Licensing of LVTS's proprietary vascular medicine IP (stent coatings, thrombectomy coatings, thrombolytic nanoparticles, biomimetic barrier models) and collaborative research services delivered to pharmaceutical, medical device and biotech partners.
• Biotech Startup Creation (LVTS's Biotechs) Creation and support of biotech startups spun out of LVTS research programs, providing founders with access to LVTS IP, research platforms, and translational expertise in vascular medicine and medical devices.

Quantifiable outcome

• SOPHIA project awarded European EIT funding (2026)
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered core, major and moderate.

• INSERM (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development PartnerPrimary institutional affiliation. INSERM is the French National Institute of Health and Medical Research, providing institutional support, funding, and research framework for LVTS as INSERM U1148.
• Université Paris Cité (UP Cité)coreStrategic or Co-development PartnerPrimary university affiliation providing academic framework, researchers, and students. LVTS is part of the UP Cité university structure.
• Université Sorbonne Paris Nord (Paris 13 University)coreStrategic or Co-development PartnerPartner university hosting teams at UFR Santé Médecine et Biologie humaine (Bobigny) and Institut Galilée (Villetaneuse).
• Plateforme Imagerie PrécliniquecoreTechnology or IntegrationPreclinical imaging platform providing advanced imaging capabilities for vascular research and validation studies.
• ERN VASCERN (European Reference Network for Rare Multisystemic Vascular Diseases)majorStrategic or Co-development PartnerEuropean reference network for rare vascular diseases, providing clinical collaboration and patient access for translational research.
• Centre de référence MARFANmajorStrategic or Co-development PartnerFrench reference center for Marfan syndrome, collaborating on vascular connective tissue disorders research.
• RHU iVASCmajorStrategic or Co-development PartnerHospital-University Research Program focused on innovative approaches for vascular diseases.
• RHU STOP-ASmajorStrategic or Co-development PartnerHospital-University Research Program addressing atherothrombotic disease in heart and brain.
• FHU INFIREmajorStrategic or Co-development PartnerFederated University Hospital structure focused on inflammatory diseases research.
• GREMI - French Society of InflammationmoderateStrategic or Co-development PartnerFrench Society of Inflammation providing collaboration network and annual meetings for inflammation-related vascular research.
• BIOMAT - French Society for BiomaterialsmoderateStrategic or Co-development PartnerFrench society for biomaterials providing conference platform and award recognition for biomaterials research.
• Purdue UniversitymoderateStrategic or Co-development PartnerInternational academic partner. LVTS hosted a tour for Purdue University researchers in May 2026 indicating ongoing collaboration.
• Université Mohammed VI Polytechnique (UM6P)moderateStrategic or Co-development PartnerMoroccan university partner offering joint doctoral cotutelle programs with Université Paris Cité, providing international research training opportunities.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lvts

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LVTS - Laboratory for Vascular Translational Science